THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this document, or the action you should take, you are recommended to seek your own personal financial advice immediately from your stockbroker, bank manager, solicitor, accountant or other independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) ("FSMA") if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

The distribution of this document to jurisdictions other than the United Kingdom may be restricted by applicable laws or regulations and this document does not form part of any offer or invitation to subscribe or sell any Ordinary Shares or constitute the solicitation of any offer to acquire or purchase Ordinary Shares in any jurisdiction where such offer, invitation or solicitation is unlawful. Persons in jurisdictions other than the United Kingdom into whose possession this document comes should inform themselves about and observe such applicable legal or regulatory requirements in such jurisdiction. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction.

If you have sold or transferred all of your registered holding of Existing Ordinary Shares, please forward this document and the accompanying Form of Proxy, as soon as possible to the purchaser or transferee, or to the stockbroker, bank or other party through whom the sale or transfer was effected, for transmission to the purchaser or transferee. If you have sold or transferred only part of your registered holding of Existing Ordinary Shares, you are advised to consult your stockbroker, bank or other party through whom the sale or transfer was effected.

Your attention is drawn to the letter from the Company's Chairman which is set out on pages 8 to 17 of this document. THE WHOLE TEXT OF THIS DOCUMENT SHOULD BE READ.

Light Science
Technologies Holdings

Light Science Technologies Holdings plc

(Incorporated and registered in England and Wales with company number 12398098)

Conditional Placing to raise £6 million at 1p per share and Retail Offer to raise up to £0.6 million at 1p per share

and

Notice of General Meeting

SHORE CAPITAL

Nominated Adviser and Broker

The Directors, whose names appear on page 8 of this document, and the Company, whose registered office appears on page 8 of this document, accept responsibility, both collectively and individually, for the information contained in this document and compliance with the AIM Rules. To the best of the knowledge of the Directors and the Company, the information contained in this document is in accordance with the facts and this document contains no omission likely to affect the import of such information.

A notice convening a General Meeting of the Company to be held at the Company's offices at The Byre, Ednaston Park Business Centre, Painters Lane, Ednaston, Ashbourne, Derbyshire, DE6 3FA at 10.00 a.m. on 9 April 2026 is set out on page 25 of this document. A Form of Proxy accompanies this document. To be valid, the Form of Proxy for use at the General Meeting must be completed and returned so as to be received by the Company's registrars, Neville Registrars Limited at Neville House, Steelpark Road, Halesowen B62 8HD not later than 10.00 a.m. on 7 April 2026. Completion and return of a Form of Proxy does not preclude Shareholders from attending the General Meeting and voting in person.

The Existing Ordinary Shares are admitted to trading on AIM. AIM is a market designed primarily for emerging or smaller companies to which a higher investment risk tends to be attached than to larger or more established companies. AIM securities are not admitted to the Official List of the Financial Conduct Authority ("**FCA**"). A prospective investor should be aware of the risks of investing in such companies and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Neither the London Stock Exchange nor the FCA has examined or approved the contents of this document. The AIM Rules for Companies are less demanding than those rules which apply to companies listed on the Official List. It is emphasised that no application is being made for admission of the Existing Ordinary Shares, the Placing Shares or the Retail Offer Shares to the Official List or to trading on the Main Market of the London Stock Exchange. Prospective investors should read this document in its entirety.

Shore Capital, which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser and sole broker to the Company in connection with the Placing. Persons receiving this document should note that Shore Capital will not be responsible to anyone other than the Company for providing the protections afforded to customers of Shore Capital or for advising any other person on the arrangements described in this document. No representation or warranty, expressed or implied, is made by Shore Capital as to the contents of this document and Shore Capital has not authorised the contents of, or any part of, this document and no liability whatsoever is accepted by Shore Capital for the accuracy of any information or opinions contained in this document or for the omission of any information. It should be noted that Shore Capital, as nominated adviser to the Company, owes certain responsibilities to the London Stock Exchange which are not owed to the Company or the Directors.

Neither this document nor any part of it constitutes or forms part of any offer to issue or sell, or the solicitation of an offer to acquire, purchase or subscribe for, any Ordinary Shares in the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Japan, New Zealand or the Republic of South Africa or any other jurisdiction in which the same would be unlawful. No public offering of Ordinary Shares is being made in any such jurisdiction.

The Ordinary Shares have not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission or other regulatory authority in the United States, nor

have any of the foregoing authorities passed upon or endorsed the merits of the Placing or the Retail Offer or the accuracy or adequacy of this document. Any representation to the contrary is a criminal offence in the United States. The relevant clearances have not been, nor will they be, obtained from the securities commission of any province or territory of Canada, no prospectus has been lodged with, or registered by, the Australian Securities and Investments Commission or the Japanese Ministry of Finance; the relevant clearances have not been, and will not be, obtained for the South Africa Reserve Bank or any other applicable body in the Republic of South Africa in relation to the Ordinary Shares and the Ordinary Shares have not been, nor will they be, registered under or offering in compliance with the securities laws of any state, province or territory of Australia, Canada, Japan, New Zealand or the Republic of South Africa. Accordingly, the Ordinary Shares may not (unless an exemption under the relevant securities laws is applicable) be offered, sold, resold or delivered, directly or indirectly, in or into Australia, Canada, Japan, New Zealand or the Republic of South Africa or any other jurisdiction outside the United Kingdom.

THE ORDINARY SHARES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "**SECURITIES ACT**"), OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. NO PUBLIC OFFERING OF THE ORDINARY SHARES IS BEING MADE IN THE UNITED STATES.

Persons (including, without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this document should seek appropriate advice before taking any action.

The financial information, certain percentages and other figures presented in this document have been subject to rounding adjustments.

All references to time in this document are to London time unless specifically stated otherwise and are subject to change. Any such change will be notified to Shareholders by an announcement through a Regulatory Information Service.

Copies of this document will be available free of charge to the public during normal business hours on any day (Saturdays, Sundays and public holidays (in England) excepted) at the Company's registered office at The Mills, Canal Street, Derby DE1 2RJ for a period of one month from the date of this document and on the Company's website https://lightsciencetechnologiesholdings.com/investors/?tab=Constitutional-Documents.

FORWARD LOOKING STATEMENTS

This document contains (or may contain) certain "forward-looking statements" with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "target", "aim", "will", "may", "would", "could", "similar", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, reflect the Directors' current beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by any such forward-looking statement. Statements contained in this document

regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this document is subject to change without notice and none of Shore Capital nor, except as required by applicable law, the Company assumes any responsibility or obligation to update publicly or review any of the forward-looking statements (or any other information) contained herein. You should not place undue reliance on forward-looking statements, which speak only as of the date of this document.

The contents of the Company's website or any hyperlinks accessible from the Company's website do not form part of this document and Shareholders should not rely on them.

CONTENTS

Page number

EXPECTED TIMETABLE OF PRINCIPAL EVENTS[1] 6

KEY STATISTICS 7

LETTER FROM THE CHAIRMAN OF LIGHT SCIENCE TECHNOLOGIES HOLDINGS PLC 8

DEFINITIONS 18

NOTICE OF GENERAL MEETING 25

EXPECTED TIMETABLE OF PRINCIPAL EVENTS[1]

	2026[2]
Announcement of the Proposals released	11 March
Publication and posting of this document	13 March
First Admission and commencement of dealings on AIM in the Firm Placing Shares	8.00 a.m. on 18 March
CREST accounts credited with the Firm Placing Shares in uncertificated form	18 March
Latest time and date for receipt of completed Forms of Proxy and CREST voting instructions for the General Meeting	10.00 a.m. on 7 April
General Meeting	10.00 a.m. on 9 April
Announcement of the results of the General Meeting	Following conclusion of the General Meeting on 9 April
Second Admission and commencement of dealings on AIM in the EIS/VCT Placing Shares	8.00 a.m. on 13 April
CREST accounts credited with the EIS/VCT Placing Shares in uncertificated form	13 April
Third Admission and commencement of dealings on AIM in the Third Placing Shares and Retail Offer Shares	8.00 a.m. on 14 April
CREST accounts credited with the Third Placing Shares and Retail Offer Shares in uncertificated form	14 April
Despatch of definitive share certificates for Fundraising Shares to be held in certificated form (where applicable)	Within 10 Business Days of the relevant Admission date

Notes:

1. All of the above times are to London times. Each of the times and dates in the above timetable is subject to change. If any of the above times and/or dates change, the revised times and dates will be notified to Shareholders by way of an announcement through a Regulatory Information Service.
2. Certain of the events in the above timetable are conditional upon, *inter alia*, the passing of the Resolutions to be proposed at the General Meeting.

KEY STATISTICS

Number of Existing Ordinary Shares in issue as at the date of this document	333,005,500
Issue Price	1p
Number of Firm Placing Shares	66,601,100
Number of Second Placing Shares	150,000,000
Number of Third Placing Shares	383,398,900
Number of Retail Offer Shares	Up to 60,000,000
Total number of new Ordinary Shares to be issued pursuant to the Fundraising[1]	660,000,000
Gross proceeds of the Fundraising[1]	£6.6 million
Estimated net proceeds of the Fundraising receivable by the Company	£6.1 million
Enlarged Share Capital immediately following First Admission	399,606,600 Ordinary Shares
Enlarged Share Capital immediately following Second Admission[2]	549,606,600 Ordinary Shares
Enlarged Share Capital immediately following Third Admission[1,2]	993,005,500 Ordinary Shares
ISIN for the Ordinary Shares	GB00BNDQJN14
SEDOL for the new Ordinary Shares	BNDQJN1

Notes:

1. Assuming full take-up under the Retail Offer.

2. Assuming the Resolutions proposed at the General Meeting are passed.

LETTER FROM THE CHAIRMAN OF LIGHT SCIENCE TECHNOLOGIES HOLDINGS PLC

(Incorporated and registered in England and Wales with registered number 12398098)

Directors:	**Registered Office:**
Graham Cooley (Non-Executive *Chairman*)	The Mills
Simon Deacon (*Chief Executive Officer*)	Canal Street
Andrew Hempsall (*Chief Operating Officer*)	Derby
James (Jim) Snooks *(Chief Financial Officer and Company Secretary)*	DE1 2RJ
Richard Mills *(Independent Non-Executive Director)*	

To Shareholders

13 March 2026

Dear Shareholder

Conditional Placing to raise £6 million at 1p per share and Retail Offer to raise £0.6 million at 1p per share

1. Introduction

On 11 March 2026, the Company announced entry into conditional agreements to acquire: (i) 100% of the share capital of RLUK Injection Ltd (**"RLUK Injection"**) (including its wholly owned subsidiary, Injectaclad Ltd (**"Injectaclad"**)); and (ii) the remaining 10% minority interest in UK Circuits and Electronics Solutions Limited ("**UK Circuits**") not already owned by UK Circuits and Electronics Solutions Holdings Ltd (**"UK Circuits Holdings"**), a subsidiary of the Company (the **"UK Circuits Acquisition"**), as well as the Property for a total maximum total consideration of up to £5.37 million (the **"Acquisitions"**). The initial consideration for the Injectaclad Acquisition is being funded through a placing (the **"Placing"**) and a separate retail offer (the **"Retail Offer"**) (the **"Fundraising"**) to raise up to £6.6 million (before expenses) at an issue price of 1 pence per share (the **"Issue Price"**). Further details of the Placing are set out below.

The net proceeds of the Fundraising will be used:

- to finance the initial consideration for the proposed acquisition of RLUK Injection (£3.0 million payable at Injectaclad Completion);
- to acquire the 10% minority interest in UK Circuits (£0.27 million) and the Property (£0.3 million plus VAT);
- for improvements and conversion at the Property (£0.2 million);
- for product development at the Company (£0.3 million); and
- to provide working capital for the Enlarged Group to facilitate large contract wins (£1.9 million).

The purpose of this document is to provide Shareholders with further information on the Acquisitions and the Fundraising (together, the "**Proposals**"). This letter explains why the Board believes that the Fundraising and the Company's intention to complete the Acquisitions, as part of its growth strategy (for which authority is being sought to issue new Ordinary Shares at the General Meeting), are in the best interests of the Company and its Shareholders as a whole, and why the Directors therefore recommend that Shareholders vote in favour of the Resolutions to be proposed at the General

Meeting, as they intend to do so in respect of their aggregate beneficial shareholdings representing approximately 32 per cent. of the Company's issued share capital.

2. Strategic Rationale

The Board has identified a compelling strategic rationale for each of the proposed Acquisitions and the associated Fundraising. The acquisition of RLUK Injection will secure the intellectual property and supply chain for the Injectaclad system, enabling the Group's Passive Fire Protection (**"PFP"**) division to accelerate its growth and capture a greater share of the value chain. The PFP division is a division in the Group with strong growth potential, and the acquisition of RLUK Injection is expected to position the Company as an industry frontrunner in passive fire protection, providing enhanced access to cavity fire barrier remediation projects and strengthening the Group's reputation as a market leader.

The acquisition of the minority interest in UK Circuits and the associated Property will consolidate the Company's ownership of the Contract Electronics Manufacturing (**"CEM"**) division, eliminate annual rental costs and unlock further value for Shareholders. The CEM division has a long track record of profitability and strong customer relationships, and the CEM Acquisition will provide full control over strategic decision-making and operational management. The Property will also be used to set up a distribution base and training centre for the PFP division.

The AGT division operates in a high-growth market, driven by rising population, climate change, and the need for greater food security and sustainability.

Overall, the Board believes that the Acquisitions and the Fundraising will position LSTH for long-term growth and value creation, providing the resources necessary to execute its strategic plan and deliver sustainable returns for Shareholders.

3. Information on RLUK Injection

RLUK Injection is the holding company of Injectaclad, which owns the patented Injectaclad fire resistant graphite barrier system. This system is a solution for the retrospective installation of cavity fire barriers in buildings using a pumped system, thereby avoiding the need for full-scale façade removal. The Injectaclad system addresses a significant problem in the UK's built environment, where thousands of buildings require remediation to meet fire safety standards introduced in the wake of the Grenfell Tower disaster. The solution is not only cost-effective and non-invasive but also environmentally friendly, as it preserves existing building façades and minimises disruption to residents and building users.

The Company's PFP division is already an installer of Injectaclad, and the Injectaclad Acquisition will secure the intellectual property and supply chain for this critical product, enabling LSTH to capture a greater share of the value chain and accelerate the growth of the PFP division. The Injectaclad Acquisition is expected to enhance the Group's reputation as an industry leader in passive fire protection and open up new opportunities for expansion in the UK and potentially internationally.

The PFP division operates as a specialist installation business, benefiting from the Fire Safety Act 2021 and the Building Safety Act 2022, as well as the £6 billion Government-led fund for national remediation works. The division offers a cost-effective and environmentally friendly solution, generating strong cash flows and margins. It is positioned with international fire consultants' 3rd party accreditation and full compliance with statutory regulations, ensuring the safe evacuation of buildings.

PFP currently has a quoted sales pipeline of approximately £24 million, pending approval from the Building Safety Regulator ("BSR"), and post-Completion will establish a base in Manchester at the CEM property. Its patented Injectaclad system provides a unique cavity barrier remediation solution, capable of expanding twenty times its size when exposed to heat, with a 50-year product lifespan. The product allows for rapid installation without façade removal, giving the division high margins and market control. With 12 approved installers nationwide and over 45 tests conducted by Warrington Fire across various cavity sizes and materials, the division is well placed to capitalise on the growing demand for safe, compliant, and efficient fire protection solutions.

The addressable market for the PFP division is estimated at £4.42 billion. The division's strategy is designed to close the gap between regulators and decision-makers, which has contributed to current BSR delays. This includes taking design responsibility through an employed fire engineer, performing large-scale product tests alongside numerous component-level assessments, and securing standardised technical details approved by the BSR. Engagement with fire engineers, architects, and end users will be increased, complemented by insurance-backed warranties offered at additional cost and publication of performance tests with the Institute of Fire Engineers and other industry bodies. On the industry side, all sales will be contracted via Injectaclad, retaining margins on installations, while the intention is to reduce the number of installers nationally from 12 to 6 (4 regional and 2 main contractors). Quality auditing will be centralised across all sites to maintain control and ensure consistent pricing based on meterage and cavity depth will ensure margin stability.

The table below sets out summary unaudited historical financial information for Injectaclad for the 3 years ended 31 December 2024 and 10 months ended 31 October 2025:

£'000	**Unaudited Year ended 31 December 2022**	**Unaudited Year ended 31 December 2023**	**Unaudited Year ended 31 December 2024**	**Unaudited 10 months to 31 October 2025**
Revenue	254	985	1,423	1,167
Gross profit	121	502	761	672
Gross profit margin	47.5%	50.9%	53.5%	57.6%
Adjusted EBITDA	9	285	471	444
Adjusted profit before tax	9	267	457	430
Reported profit before tax	9	237	457	257

Total Assets	132	406	479	240

4. Summary terms of the Injectaclad Acquisition

The Company has entered into the RLUK Injection Acquisition Agreement to acquire the entire issued share capital of RLUK Injection, together with its wholly owned subsidiary, Injectaclad. The total maximum consideration payable is £4.8 million which is payable in cash and structured in several tranches to align with both immediate and future performance objectives. The initial consideration amounts to £3.0 million which is payable upon Injectaclad Completion.

In addition to the initial consideration payment, a further £1.0 million is payable as deferred consideration, twelve months after Injectaclad Completion. Furthermore, an additional £0.8 million

may be payable as contingent consideration, subject to the achievement of defined sales revenue targets of £3.0 million in year 1; £4.0 million in year 2; and £5.0 million in year 3, following Injectaclad Completion.

The initial consideration of £3.0 million will be funded from the net proceeds of the Fundraising. Four of the largest Injectaclad Vendors by shareholding are a group of individuals with significant experience in the sector, and their continued involvement via an ongoing installer arrangement through a related party during the earn-out period is expected to facilitate a smooth transition and integration of the Injectaclad business into the Group. The RLUK Injection Acquisition Agreement includes standard warranties and indemnities in favour of the Company, providing protection against undisclosed liabilities and ensuring that the Company acquires the Injectaclad business that is free from material encumbrances.

The Injectaclad Acquisition will not result in any changes to the Board or fundamental changes to the business, as the Company is already an installer of Injectaclad products and an established participant in the passive fire protection market.

5. Information on UK Circuits

The Company is also acquiring the remaining 10% minority interest in UK Circuits, not already owned by UK Circuits Holdings, which comprises the CEM division of the Group, and the related leasehold property in Manchester. UK Circuits is a well-established provider of contract electronics manufacturing services, specialising in the design, procurement, and manufacture of high-quality printed circuit boards for a range of sectors, including audio, automotive, electronics, gas detection, lighting, pest control, and Agtech.

The UK Circuits Acquisition will consolidate the Company's ownership of this important division, providing full control over strategic decision-making and operational management. The acquisition of the leasehold property, which houses the CEM division, will eliminate annual rental costs of approximately £45,000 and unlock further value for Shareholders by increasing the total value of the CEM division and providing flexibility for future divestment or expansion. The Property will also be used to set up a distribution base and training centre for the PFP division. In the year ended 30 November 2024, UK Circuits made an audited profit before tax of £0.4 million on revenue of approximately £9.5 million and as at 31 May 2025 had unaudited net assets of approximately £0.6 million. The CEM division currently has a quoted sales pipeline of £0.7 million and forward orders totalling £2.1 million.

6. Summary terms of the UK Circuits Acquisition and Property Acquisition

The consideration payable for the minority interest in UK Circuits is £270,000, payable in cash to the UK Circuits Vendors on UK Circuits Completion. The UK Circuits Acquisition will result in UK Circuits Holdings owning 100% of UK Circuits, thereby consolidating the Company's control over the division and enabling more streamlined decision-making and operational management.

The Property Acquisition is being effected for a cash consideration of £300,000 plus VAT, payable to the Property Vendors on Property Completion. The Property is physically connected to other leasehold properties owned and already utilised by the Group, and the Property Acquisition will eliminate annual

rental costs of approximately £45,000, thereby enhancing the profitability and value of the CEM division. The Property is already utilised by the Group, and the UK Circuit Acquisition will provide greater flexibility for future expansion or divestment.

Both the UK Circuits Acquisition and Property Acquisition are being funded from the net proceeds of the Fundraising. The UK Circuits Acquisition Agreement and the Property Acquisition Agreement both include customary warranties and indemnities in favour of the buyer, ensuring that the assets are acquired free from material encumbrances and that the buyer is protected against undisclosed liabilities. The acquisitions will not result in any changes to the Board or fundamental changes to the business, as LSTH, through UK Circuits Holdings, already owns 90% of UK Circuits and consolidates it into its accounts. £0.2 million from the net proceeds of the Fundraising will be utilised for improvements and conversion at the Property.

7. Current Trading and Prospects

The Company expects to publish its audited full year results for the financial year ended 30 November 2025 ("FY25") in April 2026. During FY25, the Group continued to execute its growth strategy. Despite a challenging trading environment, the Group delivered total unaudited revenue of £8.6 million (FY24: £12.0 million), with an unaudited operating loss of £0.6 million (FY24: operating profit of £0.3 million). The CEM division contributed £6.3 million of revenue (FY24: £9.5 million) and £0.4 million of operating profit (FY24: £0.6 million), the AGT division £1.0 million of revenue (FY24: £0.8 million) and £0.3 million of operating loss (FY24: £0.5 million operating loss), and the PFP division £1.4 million of revenue (FY24: £1.8 million) and £0.3 million of operating profit (FY24: £0.6 million).

The Group's year-on-year revenue decreased, primarily reflecting lower sales from a key CEM division customer. Recovery in CEM has focused on securing defence and medical accreditations, while the PFP division pipeline is awaiting BSR approvals, which have been moved from the Health and Safety Executive to the Ministry of Housing, Communities and Local Government. The Group gross margin is uplifted, supported by strong margin contributions from the PFP and AGT divisions, with CEM targeting higher-margin defence and medical revenues. The Group's cash position at 30 November 2025 stood at £0.7 million (30 November 2024: £1.2 million), with fully utilised working capital facilities (FY24: £0.7 million). The 2026 financial year is expected to be cash generative for the Group.

Looking ahead, the Board believes that, should the Acquisitions and Fundraising complete as anticipated, the Enlarged Group will be well positioned to deliver enhanced financial performance. The Board expects that, following completion of the Acquisitions, the Enlarged Group will benefit from increased scale, broader market opportunities, and a strengthened balance sheet. Furthermore, the Board believes the Proposals will help advance the Group's five-year vision of achieving £50 million in revenue.

8. Details of the Placing and the Retail Offer

The Placing

The Company is proposing to raise gross proceeds of £6.0 million (before expenses) through a Placing of new Ordinary Shares, which is structured in three tranches to accommodate regulatory requirements.

The Placing comprises: (i) a Firm Placing; (ii) an EIS/VCT Placing; and (iii) a General Placing, with each tranche to be admitted to trading on AIM through separate admissions.

The Firm Placing Shares will be allotted and issued pursuant to the Company's existing share authorities from the AGM Resolutions and is conditional, amongst other things, upon the Company having complied with its obligations under the Placing Agreement to the extent the same fall to be performed prior to First Admission. The Firm Placing Shares will be allotted, issued and admitted to trading on as part of First Admission which is expected to be effective on 18 March 2026.

The EIS/VCT Placing Shares, which are expected to qualify for relief under the Enterprise Investment Scheme and Venture Capital Trust rules (with HMRC EIS advance assurance obtained), is conditional, amongst other things, upon: (i) the First Placing having occurred; (ii) the Resolutions set out in the Notice of General Meeting being approved by Shareholders and (iii) the Company having complied with its obligations under the Placing Agreement to the extent the same fall to be performed prior to Second Admission. The EIS/VCT Placing Shares will be allotted, issued and admitted to trading on AIM as part of Second Admission. Second Admission is expected to take place on 13 April 2026.

The General Placing Shares, representing the balance of the Fundraising, will be allotted, issued and admitted to trading on AIM as part of Third Admission. Third Admission is conditional, amongst other things, upon: (i) the EIS/VCT Placing having occurred; (ii) the Resolutions set out in the Notice of General Meeting being approved by Shareholders and (iii) the Company having complied with its obligations under the Placing Agreement to the extent the same fall to be performed prior to Third Admission. Third Admission is expected to take place on 14 April 2026.

The status of EIS Placing Shares as qualifying for EIS Relief will be conditional (amongst other things) on the qualifying conditions being satisfied, both by the Company and (as regards those conditions to be met by the investor) the investor throughout a period of at least three years from the date of issue. The status of such VCT Placing Shares as a qualifying holding for VCT purposes will be conditional (amongst other things) on the qualifying conditions being satisfied throughout the period of ownership. There can be no assurance that the Company will conduct its activities in a way that will secure or retain qualifying status for VCT and/or EIS purposes (and indeed circumstances may arise where the Directors believe that the interests of the Group are not served by seeking to retain such status).

The Issue Price of 1 pence per Placing Share is a discount of 65.5 per cent. to the closing middle market price of 2.9 pence per Existing Ordinary Share on 10 March 2026, being the last Business Day prior to the announcement of the Proposals.

The Placing Agreement

Pursuant to the terms of the Placing Agreement, Shore Capital, as agent for the Company, has conditionally agreed to use its reasonable endeavours to procure subscribers for the Placing Shares. The Placing is not being underwritten.

The Placing Agreement contains customary warranties (in relation to, inter alia, the operation of the Group's business and the financial condition of the Group and the accuracy of the information in this document) and indemnities given by the Company to Shore Capital as well as customary rights of termination for a transaction of this nature. The Company will pay Shore Capital commission in respect of those Placees procured by Shore Capital.

The Retail Offer

The Retail Offer was launched by the Company at 7.10 a.m. on 11 March 20226 and provides existing retail Shareholders in the United Kingdom with an opportunity to participate in the Fundraising at the same price as the Placing, by subscribing for Retail Offer Shares through the financial intermediaries which are listed, subject to certain access restrictions, on the Bookbuild Platform.

The Retail Offer will close at 4.30 p.m. on 16 March 2026 and, assuming it is fully subscribed, will conditionally raise gross process of up to £0.6 million (before expenses) through the issue of a maximum of 60,000,000 new Ordinary Shares ("**Retail Offer Shares**"). It is expected that the results of the Retail Offer will be announced at 7.00 a.m. on 17 March 2026.

The Retail Offer is conditional, inter alia, on the passing of the Resolutions at the General Meeting and Third Admission taking place.

9. Director participation and a Related Party Transaction

I have subscribed for 12,500,000 Placing Shares. Following completion of the Fundraising, I will hold an interest in 41,500,000 Ordinary Shares, representing approximately 4.2 per cent. of the Enlarged Share Capital (assuming the Retail Offer is fully subscribed).

Andrew Hempsall, Company's Chief Operating Officer, intends to participate in the Retail Offer. Further details will be included in the announcement to be published by the Company relating to the Retail Offer results.

Dowgate Group Limited ("**Dowgate**") (including persons associated with Dowgate) has subscribed for 103,000,000 Placing Shares. As at the date of this document, so far as the Company is aware, Dowgate holds 44,690,000 existing Ordinary Shares representing 13.42 per cent. of the Company's current issued share capital. As such, Dowgate is a substantial shareholder of the Company and its participation in the Placing is a related party transaction pursuant to Rule 13 of the AIM Rules for Companies. The Independent Directors (being Simon Deacon, James Snooks and Richard Mills, who are not participating in the Fundraising) consider, having consulted with the Company's nominated adviser, Shore Capital and Corporate, that the terms of Dowgate's participation in the Placing are fair and reasonable insofar as the Shareholders are concerned.

10. Admission, Dealings and Settlement on AIM

Application has been made to the London Stock Exchange for the First Placing Shares to be admitted to trading on AIM. It is expected that First Admission will become effective and that dealings in the First Placing Shares will commence, and at 8.00 a.m. on 18 March 2026. It is expected that the relevant CREST accounts will be credited on the same day.

Application will be made to the London Stock Exchange for the Conditional Placing Shares and Retail Offer Shares to be admitted to trading on AIM. It is expected that (subject to passing of the Resolutions at the General Meeting) Second Admission will become effective and dealings in the Second Placing

Shares will commence at 8.00 a.m. on 13 April 2026. The relevant CREST accounts are expected to be credited with the Second Placing Shares on the same day. It is expected that (subject to passing of the Resolutions at the General Meeting) Third Admission will become effective and dealings in the General Placing Shares and Retail Offer Shares will commence at 8.00 a.m. on 14 April 2026. The relevant CREST accounts are expected to be credited with the General Placing Shares and Retail Offer Shares on the same day.

The new Ordinary Shares will, on each respective Admission, rank pari passu in all respects with the Existing Ordinary Shares and will rank in full for all dividends and other distributions declared, made or paid on new Ordinary Shares after First Admission, Second Admission and Third Admission respectively. Definitive share certificates in respect of the Placing Shares and the Retail Offer Shares will be despatched within 10 Business Days of the respective date of Admission.

11. Overseas Shareholders

It is the responsibility of each Overseas Shareholder and of any person receiving a copy of this document and/or the accompanying Form of Proxy outside the United Kingdom to satisfy themselves as to the full observance of the laws and regulatory requirements of the relevant territory in connection therewith, including obtaining any governmental or other consents which may be required or observing any other formalities required to be observed in such territory. If in doubt, such persons should seek professional advice.

Persons (including, without limitation, nominees and trustees) receiving this document and/or the accompanying Form of Proxy should not distribute or send such document into any Restricted Jurisdiction or any other jurisdiction when to do so would or might contravene local securities laws or regulations. Any person who does forward this document and/or the accompanying Form of Proxy into any such jurisdictions should draw the recipient's attention to the contents of this paragraph 11.

12. General Meeting

The notice convening the General Meeting to be held at 10.00 a.m. at the Company's offices at The Byre, Ednaston Barns, Ednaston Park, Painters Lane, Ednaston, Ashbourne, Derbyshire, DE6 3FA on 9 April 2026 is set out on page 25 of this document.

Resolution 1, proposed to be passed as an ordinary resolution, grants the Directors authority to allot shares and grant rights to subscribe for or to convert any security into shares in the Company up to:

- an aggregate nominal value of £6,600,000 in connection with the Fundraising; and
- in addition to the above, with an aggregate nominal value of £2,979,016 (being approximately 30% of the anticipated Enlarged Share Capital (assuming the Retail Offer is fully subscribed)).

In addition to the Fundraising authority, the Company is seeking the additional 30% authority in a form consistent with the AGM Resolutions but calculated by reference to the anticipated Enlarged Share Capital (assuming full subscription of the Retail Offer).

The authority to be granted by Resolution 1 is in addition to the existing like authority under the AGM Resolutions and without prejudice to any allotment of shares or grant of rights to subscribe for, or to convert any security into, shares in the Company already made, offered or agreed to be made pursuant to such existing authority. Furthermore, the authority under Resolution 1 will expire on the earlier of (i) the next annual general meeting of the Company and (ii) 30 June 2026.

Resolution 2, which is conditional on the passing of the Resolution 1, is a special resolution to authorise the Directors to allot equity securities (as defined in section 560 of the Act) pursuant to the authority granted under Resolution 1 on a non pre-emptive basis and is limited to:

- the allotment of equity securities with an aggregate nominal value of £6,600,000 in connection with the Fundraising; and
- in addition to the above, the allotment of equity securities with an aggregate nominal value of £1,986,011 (being approximately 20% of the Enlarged Share Capital (assuming the Retail Offer is fully subscribed)).

In addition to the Fundraising authority, the Company is seeking the additional 20% authority in a form consistent with the AGM Resolutions but calculated by reference to the anticipated Enlarged Share Capital (assuming full subscription of the Retail Offer).

The authority to be granted by Resolution 2 is in addition to the existing like authority under the AGM Resolutions and without prejudice to such subsisting authority, and will expire on the earlier of (i) the next annual general meeting of the Company and (ii) 30 June 2026.

13. Action to be taken by Shareholders

Shareholders will find enclosed with this document a Form of Proxy for use at the General Meeting. You are strongly encouraged to complete, sign and return your Form of Proxy in accordance with the instructions printed on it as soon as possible, but in any event so as to be received, by post at Neville Registrars Limited, Neville House, Steelpark Road, Halesowen B62 8HD by no later than 10.00 a.m. on 7 April 2026 (or, in the case of an adjournment, not less than 48 hours before the time fixed for the holding of the adjourned meeting (at the discretion of the Directors, excluding any part of a day that is not a working day). Completion and return of a Form of Proxy does not preclude Shareholders from attending the General Meeting and voting in person.

The Directors also request that Shareholders vote in advance of the General Meeting either electronically, via CREST or by completing and returning the enclosed Form of Proxy as soon as possible and, in any event, so as to be received not later than 10.00 a.m. on 7 April 2026. The Resolutions set out in the Notice of General Meeting will be voted on by way of a poll. Poll voting is seen as best practice as it gives all Shareholders the opportunity to participate in the decision-making of the Company and have their votes recorded in proportion to the number of Ordinary Shares they hold. All valid proxy votes (whether submitted electronically or in hard copy form) will be included in the poll to be taken at the meeting.

If you hold your Ordinary Shares in uncertificated form (that is, in CREST) you may vote using the CREST Proxy Voting service in accordance with the procedures set out in the CREST Manual (please also refer to the accompanying notes to the Notice of the General Meeting). Proxies submitted via CREST must be received by the Company's agent (ID 7RA11) by no later than 10.00 a.m. on 7 April 2026 (or, in the case of an adjournment, not less than 48 hours before the time fixed for the holding of the adjourned meeting (at the discretion of the Directors, excluding any part of a day that is not a working day).

Appointing a proxy in accordance with the instructions set out above will enable your vote to be counted at the General Meeting.

14. Recommendation

The Directors consider the Proposals to be in the best interests of the Company and Shareholders as a whole. Accordingly, the Directors unanimously recommends that you vote in favour of the Resolutions, as they intend to do in respect of their beneficial holdings, which represent, in aggregate, approximately 32 per cent. of the Company's issued share capital.

Yours faithfully

Graham Cooley
Non-Executive Chairman

DEFINITIONS

The following definitions apply throughout this document, unless the context otherwise requires:

"Acquisitions"	together, the Injectaclad Acquisition, the UK Circuits Acquisition and the Property Acquisition
"Act"	the Companies Act 2006
"Admissions"	together, First Admission, Second Admission and Third Admission and "**Admission**" shall mean any of them as the context so requires
"AGM Resolutions"	the existing allotment and dis-application of pre-emption authorities obtained at the Company's Annual General Meeting held on 15 April 2025
"AGT" or "AgTech"	the agriculture technology division of the Group, being the business focused on the development, manufacture and commercialisation of controlled-environment agriculture, crop monitoring and related agricultural technology solutions
"AIM"	the AIM market operated by the London Stock Exchange
"AIM Rules for Companies"	the London Stock Exchange's rules and guidance notes contained in its "AIM Rules for Companies" publication relating to companies whose securities are traded on AIM, as amended from time to time
"Board" or "Directors"	the directors of the Company, or any duly authorised committee thereof
"Bookbuild Platform"	the online retail offer platform operated by BookBuild Limited
"Business Day"	a day (not being a Saturday, Sunday or public holiday in the United Kingdom) on which dealings in domestic securities may take place on, and with the authority of, the London Stock Exchange
"CEM"	the contract electronics manufacturing division of the Group, providing electronic design, manufacturing and assembly services to third-party customers and to other divisions within the Group
"certificated form" or "in certificated form"	an Ordinary Share recorded on the Company's share register as being held in certificated form (namely, not in CREST)
"Company", "LSTH" or "Light Science Technologies"	Light Science Technologies Holdings plc, a company incorporated and registered in England and Wales with registered number 12398098 whose registered office is The Mills, Canal Street, Derby DE1 2RJ
"Conditional Placing"	together, the Second Placing and the Third Placing

"Conditional Placing Shares"	the new Ordinary Shares to be issued pursuant to the Second Placing and the Third Placing, subject, *inter alia*, to Shareholder approval of the Resolutions at the General Meeting
"CREST"	the computerised settlement system (as defined in the CREST Regulations) in the UK operated by Euroclear UK & International Limited which facilitates the transfer of title to shares in uncertificated form (as defined in the CREST Regulations)
"CREST Manual"	the rules governing the operation of CREST, consisting of the CREST Reference Manual, CREST International Manual, CREST Central Counterparty Service Manual, CREST Rules, Registrars Service Standards, Settlement Discipline Rules, CCSS Operations Manual, Daily Timetable, CREST Application Procedure and CREST Glossary of Terms (all as defined in the CREST Glossary of Terms promulgated by Euroclear on 15 July 1996, as amended)
"CREST Member"	a person who has been admitted to Euroclear as a system-member (as defined in the CREST Regulations)
"CREST Regulations"	the Uncertificated Securities Regulations 2001 (S.I. 2001 No. 3755) as amended
"CREST Sponsor"	a CREST participant admitted to CREST as a sponsor
"CREST Sponsored Member"	a CREST Member admitted to CREST as a sponsored member
"Dowgate"	Dowgate Group Limited
"EIS/VCT Admission" or "Second Admission"	admission of the 150,000,000 EIS/VCT Placing Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies
"EIS/VCT Placing" or "Second Placing"	the conditional placing of the 150,000,000 EIS/VCT Placing Shares at the Issue Price by Shore Capital on behalf of the Company pursuant to the terms of the Placing Agreement
"EIS/VCT Placing Shares" or "Second Placing Shares"	the 150,000,000 new Ordinary Shares to be issued at the Issue Price pursuant to the EIS/VCT Placing subject, *inter alia*, to Shareholder approval of the Resolutions at the General Meeting, and "**EIS Placing Shares**" means those new Ordinary Shares issued to Placees seeking to invest in "eligible shares" for the purposes of EIS and "**VCT Placing Shares**" means those new Ordinary Shares which are intended to form part of the relevant Placee's "qualifying holding" (within the meaning of section 286 Income Tax Act 2007)
"Enlarged Group"	the Group as enlarged by the Acquisitions
"Enlarged Share Capital"	the new Ordinary Shares expected to be in issue immediately following admission of the First Placing Shares, Second Placing Shares, the Third Placing Shares and the Retail Offer Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies

"Enterprise Investment Scheme" or "EIS"	means the UK's Enterprise Investment Scheme, as particularised in the EIS Legislation
"EIS Legislation"	means Part 5 of the Income Tax Act 2007 and any provisions of UK or European law referred to therein and sections 150A, B and C of the Taxation of Chargeable Gains Act 1992
"EIS Relief"	means relief from UK tax under the EIS Legislation
"Euroclear"	Euroclear UK & International Limited, the operator of CREST
"Existing Ordinary Shares"	the 333,005,500 Ordinary Shares in issue as at the date of this document
"FCA"	the Financial Conduct Authority in its capacity as the competent authority
"Firm Placing" or "First Placing"	the firm placing of the 66,601,100 Firm Placing Shares at the Issue Price by Shore Capital on behalf of the Company pursuant to the terms of the Placing Agreement
"Firm Placing Shares" or "First Placing Shares"	the 66,601,100 new Ordinary Shares to be issued pursuant to the Firm Placing or as the first tranche of the Placing pursuant to the existing allotment and dis-application of pre-emption rights authorities pursuant to the AGM Resolutions
"First Admission"	admission of the Firm Placing Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies
"Form of Proxy"	the form of proxy enclosed with this document for use by Shareholders in connection with the General Meeting
"FSMA"	the Financial Services and Markets Act 2000 (as amended)
"Fundraising"	together, the First Placing, the Second Placing, the Third Placing and the Retail Offer
"Fundraising Shares"	together, the First Placing Shares, the Second Placing Shares, the General Placing Shares and the Retail Offer Shares and any one of them a "**Fundraising Share"**
"FY25"	the Company's financial year ended 30 November 2025
"General Meeting"	the general meeting of the Company to be held at the Company's offices at The Byre, Ednaston Barns, Ednaston Park, Painters Lane, Ednaston, Ashbourne, Derbyshire, DE6 3FA at 10.00 a.m. on 9 April 2026, notice of which is set out on page 25 of this document
"Group"	the Company and its subsidiaries
"Independent Directors"	Simon Deacon, James Snooks and Richard Mills, being those Directors who are not participating in the Placing
"Injectaclad"	Injectaclad Ltd, a company incorporated and registered in England and Wales with registered number 12497314 whose registered office is Roger Lewis House, Unit 6 Llandough

	Trading Estate, Penarth Road, Cardiff, CF11 8RR which is a wholly owned subsidiary of RLUK Injection
"Injectaclad Acquisition"	the proposed acquisition of RLUK Injection (and its wholly owned subsidiary, Injectaclad)
"Injectaclad Completion"	completion of the Injectaclad Acquisition
"Injectaclad Vendors"	the vendors of RLUK Injection, the holding company of Injectaclad
"ISIN"	International Securities Identification Number
"Issue Price"	1 pence per Fundraising Share
"London Stock Exchange"	London Stock Exchange plc
"Notice of General Meeting"	the notice convening the General Meeting set out on page 25 of this document
"Official List"	the Official List of the FCA
"Ordinary Shares"	the ordinary shares of 1 penny each in the capital of the Company
"Overseas Shareholders"	Shareholders with registered addresses outside the United Kingdom or who are citizens or residents of countries outside the United Kingdom
"PFP"	the passive fire protection division of the Group, focused on the development, testing, manufacture and sale of fire protection products and systems designed to prevent or limit the spread of fire, smoke and heat within buildings
"Placees"	the persons who agree conditionally to acquire the Placing Shares pursuant to the Placing
"Placing"	together, the First Placing, the Second Placing and the Third Placing
"Placing Agreement"	the conditional agreement dated 11 March 2026 between: (1) the Company: and (2) Shore Capital, relating to the terms and conditions upon which Shore Capital is engaged by the Company for the purposes of the Placing
"Placing Shares"	together, the First Placing Shares, the Second Placing Shares and the General Placing Shares
"Property"	Units A4-A5 Greengate Industrial Estate, Chadderton, Manchester M24 1SW
"Property Acquisition"	the proposed acquisition of the Property
"Property Acquisition Agreement"	the agreement dated 11 March 2026 between: (1) the Property Vendors and (2) UK Circuits in respect of the acquisition of the Property, which contains, *inter alia*, details of the consideration payable to, and the warranties and indemnities to be given by, the Property Vendors;
"Property Completion"	completion of the Property Acquisition

"Property Vendors"	the vendors of the Property
"Proposals"	together, the Acquisitions and the Fundraising
"Registrar"	Neville Registrars Limited of Neville House, Steelpark Road, Halesowen B62 8HD
"Regulatory Information Service"	means any information service authorised from time to time by the FCA for the purpose of disseminating regulatory announcements
"Resolutions"	the resolutions set out in the Notice of General Meeting
"Restricted Jurisdiction"	the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction in which the publication or distribution of this document and the accompanying Form of Proxy would breach any applicable law or regulation
"Retail Investors"	existing Shareholders who are resident in the United Kingdom and are a customer of an intermediary who agree to conditionally subscribe for Retail Offer Shares in the Retail Offer
"Retail Offer"	the separate offer by the Company of the Retail Offer Shares, through the Bookbuild Platform, to Retail Investors
"Retail Offer Shares"	up to 60,000,000 new Ordinary Shares to be allotted and issued at the Issue Price pursuant to Retail Offer, conditional on, *inter alia*, the passing of the Resolutions at the General Meeting, at the Issue Price pursuant to the Retail Offer
"RLUK Injection"	RLUK Injection Ltd, a company incorporated and registered in England and Wales with registered number 14391757 whose registered office is Roger Lewis House, Unit 6 Llandough Trading Estate, Penarth Road, Cardiff, CF11 8RR
"RLUK Injection Acquisition Agreement"	the agreement dated 11 March 2026 between: (1) the Injectaclad Vendors; and (2) the Company in respect of the acquisition of RLUK Injection (and its wholly owned subsidiary, Injectaclad), which contains details of the consideration payable to, and the warranties and indemnities to be given by, the Injectaclad Vendors
"Second Admission"	admission of the Second Placing Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies
"Second Placing"	the conditional placing of the Second Placing Shares at the Issue Price pursuant to the Placing Agreement
"Securities Act"	the US Securities Act of 1933, as amended
"Shareholders"	holders of Ordinary Shares, from time to time;
"Shore Capital"	together, Shore Capital and Corporate and Shore Capital Stockbrokers;
"Shore Capital and Corporate"	Shore Capital and Corporate Limited, a company incorporated and registered in England and Wales with registered number

	02083043 whose registered office is Cassini House, 57 St James's Street, London, England, SW1A 1LD
"Shore Capital Stockbrokers"	Shore Capital Stockbrokers Limited, a company incorporated and registered in England and Wales with registered number 01850105 whose registered office is Cassini House, 57 St James's Street, London, England, SW1A 1LD
"Third Admission"	admission of General Placing Shares and the Retail Offer Shares to trading on AIM becoming effective in accordance with the AIM Rules for Companies
"Third Placing" or "General Placing"	the conditional placing of General Placing Shares at the Issue Price pursuant to the Placing Agreement
"Third Placing Shares" or "General Placing Shares"	means the 383,398,900 new Ordinary Shares to be issued at the Issue Price pursuant to the Third Placing, which are not Firm Placing Shares, EIS Placing Shares or VCT Placing Shares, subject, *inter alia*, to Shareholder approval of the Resolutions at the General Meeting
"UK Circuits"	UK Circuits and Electronics Solutions Limited, a company incorporated and registered in England and Wales with registered number 03301172 whose registered office is The Mills, Canal Street, Derby, DE1 2RJ, which is a 90% subsidiary of UK Circuits Holdings
"UK Circuits Acquisition"	the proposed acquisition of the 10% shareholding in UK Circuits not already owned by UK Circuits Holdings
UK Circuits Acquisition Agreement	the agreement dated 11 March 2026 between: (1) the UK Circuits Vendors and (2) UK Circuits Holdings in respect of the acquisition of the minority shareholding in UK Circuits not owned by UK Circuits Holdings, which contains details of the consideration payable to, and the warranties and indemnities to be given by, the UK Circuits Vendors
"UK Circuits Completion"	completion of the UK Circuits Acquisition
"UK Circuits Holdings"	UK Circuits and Electronics Solutions Holdings Limited, a company incorporated and registered in England and Wales with registered number 09955364 whose registered office is The Mills, Canal Street, Derby, DE1 2RJ, which is a wholly owned subsidiary of the Company
"UK Circuits Vendors"	the vendors of the minority shareholding in UK Circuits not owned by UK Circuits Holdings
"UK" or "United Kingdom"	the United Kingdom of Great Britain and Northern Ireland
"uncertificated" or "in uncertificated form"	recorded on the relevant register of the share or security concerned as being held in uncertificated form in CREST and title to which, by virtue of the CREST Regulations, may be transferred by means of CREST
"United States" or "US"	the United States of America, its territories and possessions, any state of the United States of America and the District of Columbia and all areas subject to its jurisdiction

“VCT” or “Venture Capital Trust”	a company which is, or which is seeking to become, approved as a venture capital trust under the provisions of Part 6 of the ITA
“working day”	has the meaning given in section 1173 of the Act

All references in this document to “£”, “pence”, “p” or “pounds sterling” are to the lawful currency of the UK.

LIGHT SCIENCE TECHNOLOGIES HOLDINGS PLC

(Incorporated and registered in England and Wales with company number 12398098)

NOTICE OF GENERAL MEETING

Notice is hereby given that a General Meeting of Light Science Technologies Holdings plc (**Company**) will be held at 10.00 a.m. at the Company's offices at The Byre, Ednaston Barns, Ednaston Park, Painters Lane, Ednaston, Ashbourne, Derbyshire, DE6 3FA on 9 April 2026 for the purposes of considering and if thought fit passing the following resolutions (the "**Resolutions**") (in which capitalised terms shall have the meanings given in the circular to shareholders issued by the Company dated 13 March 2026, containing this Notice of General Meeting , save where otherwise specified).

PLEASE REFER TO THE NOTES BELOW THE RESOLUTIONS.

You will be asked to consider and vote on the Resolutions below. Resolution 1 will be proposed as an ordinary resolution and Resolution 2 will be proposed as a special resolution.

Ordinary Resolution

Resolution 1 – That, in accordance with section 551 of the Companies Act 2006 (**Act**) and in addition to any existing like authority (and without prejudice to any allotment of shares or grant of rights to subscribe for, or to convert any security into, shares in the Company already made, offered or agreed to be made pursuant to such authority), the directors of the Company from time to time be generally and unconditionally authorised to exercise all powers of the Company to allot shares in the Company or grant rights to subscribe for or convert any security into shares in the Company ("**Rights**"), provided that such authority shall be limited to:

(a) the allotment of shares and/or grant of Rights with an aggregate nominal value of £6,600,000 in connection with the Fundraising; and

(b) in addition to sub-paragraph (a) above, the allotment of shares and/or grant of Rights with an aggregate nominal value of £2,979,016 (being approximately 30% of the anticipated Enlarged Share Capital following completion of the Fundraising),

provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the earlier of (i) the next annual general meeting of the Company and (ii) 30 June 2026, save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or Rights to be granted and the Directors may allot shares or grant Rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.

Special Resolution

Resolution 2 – That subject to the passing of Resolution 1 above, the directors of the Company from time to time be generally authorized, in accordance with section 570 of the Act and in addition and without prejudice to any subsisting like authority, to allot equity securities (as defined in section 560(1) of the Act) for cash, under the authority given by Resolution 1, as if section 561(1) of the Act did not apply to any such allotment, provided that such authority shall be limited to:

(a) the allotment of equity securities with an aggregate nominal value of £6,600,000 in connection with the Fundraising; and

(b) in addition to sub-paragraph (a) above, the allotment of equity securities with an aggregate nominal value of £1,986,011 (being approximately 20% of the anticipated Enlarged Share Capital following completion of the Fundraising),

provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the earlier of (i) the next annual general meeting of the Company and (ii) 30 June 2026 , save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be granted and the Directors may allot equity securities in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.

By order of the Board,

James Snooks

Company Secretary
Dated: 13 March 2026

Registered Office:

The Mills
Canal Street
Derby
DE1 2RJ

NOTES TO THE NOTICE OF GENERAL MEETING

1. Entitlement to vote

Voting at the General Meeting will be by poll vote, which will include proxy votes, by appointing the chairman of the meeting as your proxy in accordance with the guidance set out below.

Pursuant to Part 13 of the Companies Act 2006 and to Regulation 41 of the Uncertificated Securities Regulations 2001 (as amended), only those members entered on the register of members of the Company (the "**Register**") at the close of business on 7 April 2026 or, in the event that this meeting is adjourned, on the Register 48 business hours before the time fixed for the adjourned meeting, shall be entitled to vote on the Resolutions in respect of the number of Ordinary Shares registered in their names at that time. Changes to the entries on the Register after the close of business on 7 April 2026 or, in the event that this meeting is adjourned, on the Register after 48 business hours before the time fixed for the adjourned meeting, shall be disregarded in determining the rights of any person to vote on the Resolutions. This is the time specified by the Company for the purposes of regulation 41 of the Uncertificated Securities Regulations 2001.

Shareholders are requested to vote in advance of the General Meeting either electronically via CREST or by completing and returning the enclosed Form of Proxy not later than 10.00 a.m. on 7 April 2026 (or in the case of an adjournment, not less than 48 hours before the time fixed for the holding of the adjourned meeting (at the discretion of the Directors, excluding non-working days)).

If you wish to attend the General Meeting in person, please bring some form of identification (such as driver's licence or bankcard) and present this to the Company's reception desk on arrival.

The results will be released via a Regulatory Information Service and will be published on our website https://lightsciencetechnologiesholdings.com/investors/

2. Appointment of proxies

A Shareholder entitled to attend and vote at the General Meeting is entitled to appoint one or more proxies to vote instead of him/her/it. A Shareholder may appoint more than one proxy in relation to the General Meeting provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that Shareholder. A proxy need not be a member of the Company. A proxy form may be used to make such an appointment.

A Form of Proxy is enclosed with this notice. The notes on the Form of Proxy give instructions on the appointment of a proxy. To be valid, a Form of Proxy, and the original or duly certified copy of the power of attorney or other authority (if any) under which it is signed or authenticated, should reach the Company's registrars, Neville Registrars Limited, at Neville House, Steelpark Road, Halesowen, B62 8HD, by no later than 10.00 a.m. on 7 April 2026 (or in the case of an adjournment, not less than 48 hours before the time fixed for the holding of the adjourned meeting (at the discretion of the Directors, excluding non-working days)). Completion and return of a Form of Proxy does not preclude Shareholders from attending the General Meeting and voting in person.

In the case of joint holders of shares, the vote of the first named in the register of members who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of other joint holders.

3. CREST proxy voting

CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual. CREST Personal Members or other CREST Sponsored Members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST Sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message ("**CREST Proxy Instruction**") must be properly authenticated in accordance with Euroclear UK & International Limited's specifications, and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by our Registrars, Neville Registrars Limited (ID 7RA11), by 10.00 a.m. on 7 April 2026 (or in the case of an adjournment, not less than 48 hours before the time fixed for the holding of the adjourned meeting (at the discretion of the Directors, excluding non-working days)). For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instruction to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST Sponsors, or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider, to procure that his/her/its CREST Sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST Sponsors or voting system providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001 (as amended).

4. Voting by corporate representatives

A Shareholder that is a company or other organisation not having a physical presence cannot attend in person but can appoint someone to represent it. This can be done in one of two ways: either by the appointment of a proxy (described in paragraph 2 and 3 above) or of a corporate representative. Shareholders considering the appointment of a corporate representative should check their own legal position, the Company's articles of association and the relevant provision of the Companies Act 2006.

5. Information Rights

Any person to whom this notice is sent who is a person nominated under section 146 of the Companies Act 2006 to enjoy information rights ("**Nominated Person**") may, under an agreement between him/her and the Shareholder by whom he/she was nominated, have a right to be appointed (or to have someone else appointed) as a proxy for the General Meeting. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he/she may, under any such agreement, have a right to give instructions to the Shareholder as to the exercise of voting rights

6. Shareholders rights & proxies

The statement of the rights of shareholders in relation to the appointment of proxies in paragraph 2 above does not apply to Nominated Persons. The rights described in these paragraphs can only be exercised by Shareholders of the Company.

7. Copy of Notice available on website

A copy of this Notice of General Meeting, and other information required by section 311A of the Companies Act 2006, can be found at: https://lightsciencetechnologiesholdings.com.

8. Electronic address restrictions

Any electronic address provided either in this Notice or any related documents (including the Chairman's letter and Form of Proxy) may not be used to communicate with the Company for any purposes other than those expressly stated.

9. Total voting rights

As at 12 March 2026 (being the last Business Day prior to the date of this Notice of General Meeting) the Company's issued share capital comprised 333,005,500 ordinary shares of 1 penny each, carrying one vote each. No shares are held in treasury by the Company. Therefore, the total voting rights in the Company as at 12 March 2026 is 333,005,500.

10. Explanatory notes

The explanatory notes to the Resolutions included in this Notice of General Meeting are for the information of Shareholders only and do not form part of the Resolutions to be proposed to the General Meeting.

NOTICE OF AVAILABILITY

The Notice of General Meeting and Circular to which this Proxy Form relates are available on the Company's website at https://lightsciencetechnologiesholdings.com/

NOTES TO THE FORM OF PROXY

1 If you wish to appoint some other person as your proxy please insert his/her name, initial and strike out the words 'the Chairman of the Meeting'. A proxy need not be a member of the Company. Appointing a proxy will not preclude you from personally attending and voting at the meeting (in substitution for your proxy vote) if you subsequently decide to do so. If no name is entered, the return of this form, duly signed, will authorise the Chairman of the meeting to act as your proxy.

2 Please indicate with an X in the appropriate box how you wish your vote to be cast. Unless otherwise instructed the proxy will exercise his/her discretion as to whether, and if so how he/she will vote. Unless instructed otherwise, the proxy may also vote or abstain from voting as he or she thinks fit on any other business which may properly come before the meeting (including amendments to resolutions). You may appoint more than one proxy provided each proxy is appointed to exercise rights attaching to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy please contact the Registrars of the Company as detailed in note 4 below.

3 This Form of Proxy must, in the case of an individual, be signed by the appointer or his/her attorney or, in the case of a corporation, be given under its common seal or signed on its behalf by an attorney or a duly authorised officer or, if it is subject to the Companies Act 2006 (as amended), in accordance with Section 44 thereof.

4 To be valid this Form of Proxy and any power of attorney or other authority under which it is executed (or a duly notarised copy thereof) must be lodged with the Registrars of the Company, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen B62 8HD not later than 10:00 a.m. on 7 April 2026 or not less than 48 hours (excluding non-working days) before the time appointed for the adjourned meeting at which it is to be used.

5 CREST members who wish to appoint a proxy or proxies by using the CREST electronic appointment service may do so by using the procedures described in the CREST Manual. To be valid, the appropriate CREST message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instructions given to a previously appointed proxy, must be transmitted so as to be received by our agent Neville Registrars Limited (CREST ID: 7RA11) by 10:00 a.m. (UK time) on 7 April 2026. See the notes to the Notice of Meeting for further information on proxy appointments through CREST.

6 In the case of joint holders of a share the vote of the senior who tenders a vote whether in person or by proxy shall be accepted to the exclusion of the votes of the other joint holders and for this purpose seniority shall be determined by the order in which the names stand in the statutory register of members in respect of the share.

7 Any alteration in this Form of Proxy must be initialled by the person in whose hand it is signed or executed.

8 The 'Vote Withheld' option is provided to enable you to abstain on any particular resolution. However, it should be noted that a 'Vote Withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.

Please complete and return this Form of Proxy to the Registrar at the address shown overleaf. If you wish to use an envelope, please address it to 'FREEPOST NEVILLE REGISTRARS'. If it is posted outside the United Kingdom, please return it in an envelope using the address shown overleaf and pay the appropriate postage charge.

Light Science Technologies Holdings plc

FORM OF PROXY

(Incorporated and registered in England and Wales with registered number 12398098)

I/We _____ being (a) member(s) of the Company and entitled to vote at the General Meeting, hereby appoint

(Please only complete if appointing someone other than the Chairman of the Meeting)

or failing him/her, the Chairman of the meeting as my/our proxy, to attend, speak and vote for me/us and on my/our behalf at the General Meeting of the Company, to be held on 9 April 2026 at The Byre, Ednaston Park Business Centre, Painters Lane, Ashbourne, DE6 3FA at 10:00 a.m. and at any adjournment thereof.

Resolutions (*Special Resolution)

		FOR	AGAINST	WITHHELD
1	To authorise the Directors to allot shares in the Company	☐	☐	☐
2*	To disapply statutory pre-emption rights	☐	☐	☐

If you are planning to attend the General Meeting, please tick the following box: ☐

Mark this box with an "X" if you are appointing more than one proxy: ☐

Leave blank to authorise your proxy to act in relation to your full entitlement or enter the number of shares in relation to which your proxy is authorised to vote:

Signed:

Date: D D - M M - Y Y

>123-0

NEVILLE REGISTRARS

Light Science Technologies Holdings plc

Attendance Card

The General Meeting will start at 10:00 a.m. and is being held on 9 April 2026 at The Byre, Ednaston Park Business Centre, Painters Lane, Ashbourne, DE6 3FA.

If you plan to attend the General Meeting, please bring this card with you to ensure you gain entry as quickly as possible.

Please present this card at the registration desk. It will be used to show that you have the right to attend, speak and vote at the General Meeting.

>123-0
Name
Address 1
Address 2
Address 3
Address 4
Address 5
Address 6

NEVILLE REGISTRARS

Business Reply Plus
Licence Number
RTZE-YRRG-ETSK

NR 1

Neville Registrars Limited
Neville House
Steelpark Road
Halesowen
B62 8HD